MH Guide 5.2 – Improved focus. Greater flexibility. Better usability.

When it comes to targeted cancer treatments, new biomarkers are continually found, and additional treatment options are approved. Keeping pace with those changes with MH Guide 5.2.

Noteworthy updates include:

• Regulatory agency information to focus on locally approved biomarkers
• Multiple variants can be simultaneously managed with just a few clicks
• Improved display of HRD and MSI scores

Read more